What Is a Mesothelioma Clinical Trial?
A clinical trial is a carefully controlled study on human participants that attempts to develop new and more effective ways to help people with a particular disease.
Mesothelioma clinical trials are meant to advance treatment options for victims of malignant mesothelioma. This includes patients with malignant pleural mesothelioma and peritoneal mesothelioma.
Many of today’s standard mesothelioma treatment options such as chemotherapy and targeted radiation were first tested in clinical trials to show safety and effectiveness before becoming available to the public.
Reasons patients may sign up for clinical trials include:
- Being diagnosed with a hard-to-treat type of mesothelioma such as late-stage or sarcomatoid mesothelioma
- Failure to respond to chemotherapy and/or radiation
- Mesothelioma that has come back after being in full or partial remission (recurrence)
- A desire to help future mesothelioma patients
- Being unable to afford treatment outside of a clinical trial
Participating in a clinical trial can be an attractive option for a wide range of mesothelioma patients, offering the opportunity to receive the most cutting-edge treatments based on the latest expert research.
Mesothelioma patients interested in participating in clinical trials should speak with their doctor to see if a trial is right for them. Download our Free Questions to Ask Your Doctor Checklist so you can feel fully prepared at your next appointment.
- The clinicaltrials.gov database listed 125 actively recruiting mesothelioma clinical studies across the United States as of December 2022.
- The U.S. Food and Drug Administration (FDA) has strict laws and requirements to protect participants in clinical trials. According to the National Cancer Institute (NCI), clinical trials are only performed after years of lab research shows that a treatment is safe.
- NCI says the number one target for cancer immunotherapy is a protein called WTI. In 2020, the first mesothelioma patient entered a clinical trial testing a cancer vaccine capable of targeting this protein.
- Studies are underway on the use of photodynamic therapy (PDT) in the fight against mesothelioma. For treatment, doctors inject a light-activated drug into a vein that eventually collects in cancer cells. After a few days, doctors activate the light with the goal of killing the cancerous cells.
Benefits of Mesothelioma Clinical Trials
Clinical trials are essential to the treatment of mesothelioma, which often does not respond well to standard cancer treatment options (surgery, chemotherapy, and radiation).
Benefits of Mesothelioma Clinical Trials for Patients
Many of the most effective treatments for mesothelioma can only be performed on a small fraction of patients who are diagnosed early in the disease’s progression.
This means that patients who are not responding to routine treatment or whose disease returns are often out of standard options, but they do have the option of clinical trials.
Clinical trials offer alternative treatment options to patients who:
- Are not considered good candidates for standard treatment
- Do not see improvement from standard treatment
- Have a bad reaction to standard treatment methods
- Have their mesothelioma return after treatment
By participating in clinical trials for mesothelioma, patients not only get care from top specialists using the most advanced treatments — they also benefit everyone seeking to fight mesothelioma and anyone who will become a victim of this deadly cancer in the future.
Amy Fair, a nurse with over 20 years of mesothelioma experience, explains what clinical trials are, the types, and how to find them. View Transcript.
Duration: 1 min 31 sec
Besides the standard treatment right now of radiation, surgery, and chemotherapy there are ongoing clinical trials at some facilities that some patients may fit.
Clinical trials are the development of new and novel therapies.
You have to be a candidate and meet certain criterial for clinical trials. Some trials evolve around a certain type of mesothelioma. Some evolve around a certain age group.
There are exciting clinical trials out there now that involved immunotherapy, where they are strengthening and enhancing someone’s immune system to fight the disease. There are target and gene therapies currently in clinical trials that target someone’s DNA make up and molecular studies. These are still currently in several phases of clinical trials.
If you are interested in a clinical trial or your oncologist thinks you’re a candidate for a clinical trial the best way to learn is to start with your oncologist. They should be very knowledgeable about the clinical trials in your area. The National Institute of Health, on their website, has a tremendous amount of knowledge about clinical trials, the different phases that they are in and where these facilities are at that are involved in these clinical trials.
Benefits of Mesothelioma Clinical Trials for the Medical Community
Clinical trials have important benefits for the broad mesothelioma medical community. Trials are subject to outside review and all information is reviewed by multiple nurses and doctors.
Given that mesothelioma is a relatively rare form of cancer, clinical trials add new knowledge to the existing body of research.
Clinical trials tell doctors about the unique behavior of mesothelioma, how to effectively treat it, and methods for preventing it from spreading and recurring.
Clinical trials answer important questions for the medical community. Their results lead to deeper investigations so doctors become better at managing and treating mesothelioma and extending patient survival.
Numerous people with mesothelioma are now living longer due to cancer research discoveries made in clinical trials. Reach out to the Patient Advocates at Mesothelioma Hope to learn more about clinical trials near you.
Our trusted advocates with 65+ years combined experience are ready to assist you.
Mesothelioma Prognosis After a Clinical Trial
A mesothelioma prognosis describes the way a mesothelioma patient’s cancer is expected to progress. The prognosis for mesothelioma is generally poor, with only around 10% of pleural mesothelioma patients surviving 5 years after diagnosis, according to the American Cancer Society (ACS).
However, treatments being tested through clinical trials may improve the prognosis of some mesothelioma patients.
The ACS has noted these promising new mesothelioma treatment options:
- Alternating electric fields: A portable device called NovoTTF-100L generates electric currents that may affect tumor cells more than healthy cells.
- Gene therapy: Gene therapy attempts to add new genes to cancer cells so that they are easier to destroy. This is a newer treatment type for mesothelioma clinical trials.
- Immunotherapy: Immunotherapy helps the body’s own immune system find and destroy cancer cells more effectively. Clinical trials are currently testing new immunotherapy drugs and exploring how these drugs can be best combined with other treatments for mesothelioma.
- New approaches to standard treatment: Many clinical trials are focused on testing novel approaches to standard treatment for mesothelioma or improved technologies for delivering standard treatment. Some examples are a more accurate radiation therapy device or a certain combination of chemotherapy drugs.
- Photodynamic therapy (PTD): This treatment uses a light-activated drug that is injected into the body and then later “turned on” to kill cancer cells.
- Targeted therapy: Targeted therapy hones in on the unique traits of cancer cells to kill the cancer while leaving healthy cells alone. Targeted therapy drugs that attack mesothelioma cells are coming into use and being actively studied.
It is important to remember, however, that clinical trials exist to test the effectiveness of a new treatment, so doctors cannot say how helpful a treatment will generally be for a patient. They are not beneficial for every individual participant.
“We have a lot of hope for our clinical trials. We wouldn’t be doing them if we didn’t. But they take more time from patients and the benefit is uncertain, which is why we’re testing them.”
– Christine Alewine, MD, PhD, National Cancer Institute
Patients should consider multiple factors when considering how likely a clinical trial is to help them, including the newness of the treatment approach and the phase of the study.
Clinical Trial Phases
Mesothelioma clinical trials study a wide range of topics and are split into phases to ensure optimal safety and benefits.
Mesothelioma clinical trial phases start with smaller study populations that eventually grow from stage to stage if the treatment method being researched shows positive effects.
Preclinical Trial
Initial tests are conducted on animals or in vitro human cells (cells in a lab) to see if the proposed treatment is safe for humans.
Phase 0
Small studies (10-15 people) focus on how the treatment will affect the human body.
Phase 1
These studies focus on determining the most tolerated dosage, the safest way to administer the treatment, and any associated side effects.
These elements are determined by dividing the study population into groups with increasing dose levels to see how the treatment affects each and to choose the dose for the next phase.
Phase 2
Information gathered in Phase 1 is used to see if the treatment is effective in fighting mesothelioma.
Phase 2 clinical trials study populations generally smaller than 100 people.
Phase 3
The researched treatment is administered to two similarly selected groups of patients. One group gets the new treatment and the other gets a placebo (a substance with no therapeutic value) or standard therapy.
Patients are often assigned randomly into a group and double-blinded. That means that neither those conducting the study nor the patient know which group they have been assigned. This helps researchers understand if the proposed treatment is more effective than standard treatments.
FDA Approval
The new mesothelioma treatment is submitted to the FDA for an extensive review of all of the research. A decision is made at the end of the review period as to whether the treatment is safe and effective, and therefore, should be made available to the public.
Phase 4
After the drug is approved, long-term aftermarket studies may be conducted. These trials explore the impacts of the new therapy in greater detail to better understand the benefits and risks.
Patients should educate themselves on the various types and phases of clinical trials before deciding to participate.
Types of Clinical Trials for Mesothelioma
There are many types of clinical trials. If patients meet the eligibility requirements, they may have an opportunity to participate and benefit from research in various aspects of mesothelioma prevention, treatment, and management.
Types of mesothelioma clinical research studies include:
- Prevention studies: Look at ways of preventing mesothelioma from occurring or recurring
- Screening studies: Look at improving or developing new mesothelioma detection methods
- Diagnostic studies: Test methods for earlier identification of mesothelioma in patients with symptoms
- Treatment studies: Test new treatment options, including new combinations of drugs and new approaches to standard treatment (surgery, radiation, and chemotherapy)
- Quality of life studies: Explore ways to manage symptoms of mesothelioma and the side effects of treatment
Clinical trials may attempt to develop improved methods for detecting mesothelioma at an earlier stage of disease to give patients the best possible prognosis.
Detecting mesothelioma early can be extremely challenging. For this reason, developing improved screening methods is a high priority within the medical community.
Mesothelioma Prevention
Researchers are testing new ways to reduce incidents of mesothelioma or controlling mechanisms to prevent it from recurring (coming back after treatment).
Since mesothelioma generally develops over years of exposure to asbestos, clinical trials focused on disease prevention usually involve participants who are in remission (when visible signs of mesothelioma are gone) and whose time-course is much shorter.
Mesothelioma Diagnosis
Medical researchers are looking for better ways to diagnose mesothelioma, as the rare disease can be difficult for even experienced mesothelioma doctors to distinguish from other forms of cancer.
As misdiagnosis leads to an ineffective treatment plan and a poor prognosis, many clinical trials are dedicated to improving mesothelioma diagnosis methods.
Mesothelioma Treatment
Given the relatively low survival rates of mesothelioma, the majority of clinical trials are committed to finding improved mesothelioma treatment methods to increase patient survival.
These clinical trials may test new drug combinations or procedures within standard treatment methods (chemotherapy, surgery, and radiation) or the effectiveness of alternative therapies. For example, scientists are developing drugs derived from plants and animals and testing them in the fight against mesothelioma.
Mesothelioma Management
If a patient’s mesothelioma has progressed to the point where surgery is not possible, doctors may prescribe other treatments to help manage mesothelioma symptoms and increase their quality of life.
Mesothelioma management clinical trials may focus on improving quality of life through:
- New diets that improve overall health and a patient’s ability to fight mesothelioma
- Social supports that make patients feel more connected and empowered
- Pain management methods that improve comfort in the final stages of life
All of these mesothelioma clinical trial types play an important role in helping mesothelioma victims live longer and better with their disease.
Reach out to our Patient Advocates at (866) 608-8933 now.
What to Expect During a Mesothelioma Clinical Trial
The idea of undergoing a clinical trial may intimidate some mesothelioma patients. However, patients can rest assured that clinical trials in the United States are performed under strict oversight and to the highest ethical standard to protect the safety of patients.
Clinical trials usually require additional treatments and checkups.
Mesothelioma clinical trials may require more frequent:
- Blood tests
- Imaging tests
- Medical visits and monitoring
- Medications and other treatment
Individuals considering participating in a clinical trial should speak to their loved ones and doctor about the details of a particular trial. For example, they should make sure that they understand the treatment frequency, length of the trial, restrictions, and travel requirements.
Where Do Mesothelioma Clinical Trials Take Place?
In general, clinical trials take place in the same location where a patient would receive standard mesothelioma treatments. Many clinical trials for mesothelioma take place at top mesothelioma cancer centers.
Mesothelioma clinical trials may take place at:
- Cancer centers
- Clinics
- Doctors offices
- Hospitals
However, the location of a mesothelioma clinical trial ultimately depends on the therapy or technique that the trial is testing, as well as the phase of the trial.
These studies can take place in a single location, with a small study population, or across numerous hospitals, involving thousands of mesothelioma patients throughout the country.
Clinical trials are usually conducted in larger city centers, so many patients may need to travel in order to participate.
Clinical Trial Costs
There is typically little to no cost to mesothelioma patients for experimental treatment. The government or the company testing the drug often takes care of expenses.
However, mesothelioma patients will still need to cover the costs of standard treatment. In addition, there may be extra costs associated with participating in a clinical trial.
Clinical trial costs may include:
- Doctor visits
- Hospital stays
- Lab tests
- Lodging
- Imaging tests (X-rays, etc.)
- Transportation
Depending on the study and the individual participating, some or even all of these costs may be covered.
Treatment expenses may be covered by:
- Companies sponsoring larger studies
- Government-sponsored programs
- Private health insurance
- Medicaid
- Medicare
Several factors may affect a patient’s insurance coverage of a clinical trial and related expenses.
A mesothelioma clinical trial’s consent form should include information about potential costs to participants and what is covered by the sponsor of the clinical trial.
Patients can reach out to their doctor and cancer care team for help with the details of a particular trial and how to cover associated costs.
Some patients may be eligible to pursue a mesothelioma settlement, asbestos trust fund claim, and other types of financial compensation to help pay for treatment costs.
Get your Free Mesothelioma Guide shipped overnight to learn more about different forms of financial assistance for patients and their families.
Are Clinical Trials Safe?
Clinical trials are generally safe, but as with all treatments, medical specialists cannot guarantee that experimental treatments will not cause participants any harm.
Potential risks and downsides of mesothelioma clinical trials include:
- Additional expenses
- Loss of an opportunity to pursue other treatments
- More required visits
- Side effects
- Treatment that does not improve a patient’s mesothelioma
However, the federal government has several rules and regulations in place to protect participants from unreasonable risks and to ensure that patients are properly informed of the details of a clinical trial before signing up for one.
Some general protective measures U.S. clinical trials follow are:
- Only testing on patients after a treatment is proven safe in laboratory animals
- Requiring a consent form to ensure participants understand key facts about a study
- Requiring several phases of a clinical trial and close monitoring of patients before testing on larger populations
Top mesothelioma cancer centers and other well-regarded medical facilities often enforce their own measures on top of federal requirements to further protect participants.
Top medical research centers are required to take safety measures such as:
- Setting up review boards to consider all research proposals
- Regular reviews of clinical trials throughout the research process
- Reviews from specialty committees and colleagues outside the institution
If a new mesothelioma treatment has made it to the clinical trial stage, it means that these therapies are considered reasonably safe and may improve patient prognosis.
A good result from an experimental treatment is far from guaranteed, however, and patients should speak with their doctor about a particular clinical trial and its potential risks.
How to Find a Mesothelioma Clinical Trial
There are many resources available for finding suitable clinical trials for mesothelioma, but some of the first to turn to are mesothelioma doctors and other medical care team members.
These experienced professionals are often aware of the latest treatments in development for mesothelioma and can make recommendations.
Resources for finding new clinical trials for mesothelioma include:
- Cancer center websites
- Clinicaltrials.gov
- Mesothelioma doctors
- Other members of a patient’s medical care team
- The National Cancer Institute (NCI)
Patients may wish to check multiple resources to consider as many options as possible.
For mesothelioma clinical trials found online, patients should check the requirements and current recruitment status (listed clinical trials may be closed to new participants) and then check with their doctor to see if they are able to participate.
List of Clinical Trials for Mesothelioma
Many mesothelioma clinical trials are currently being conducted in the United States.
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
- Nsclc
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Drug: AMXT1501
- Drug: DFMO
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutch Cancer Center - Seattle Cancer Care Alliance, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Drug: Nivolumab Injection
- Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore, Maryland
- Johns Hopkins University, Baltimore, Maryland
- University of Texas M.D. Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Biological: gavo-cel
- Drug: fludarabine
- Drug: cyclophosphamide
- University of California, San Francisco, San Francisco, California
- University of Miami Sylvester Cancer Center, Miami, Florida
- University of Chicago Medical Center, Chicago, Illinois
- National Cancer Institute, Bethesda, Maryland
- Columbia University Medical Center, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- University of Pennsylvania, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
- Malignant Pleural Mesothelioma (MPM)
- Drug: cyclophosphamide
- Biological: CAR T cells
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma, Malignant
- Mesothelioma Peritoneum
- Biological: TC-510
- Drug: Fludarabine
- Drug: Cyclophosphamide
- National Cancer Institute, Bethesda, Maryland
- Montefiore Einstein Cancer Center, Bronx, New York
- Sarah Cannon Research Institute, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- Peritoneal Carcinomatosis
- Peritoneal Mesothelioma
- Procedure: Heated Intraperitonial Chemotherapy
- Drug: Oxaliplatin
- Drug: 5-Fluorouracil
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
- Mesothelioma
- Mesothelioma Malignant
- Mesothelioma; Lung
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Mesothelioma; Omentum
- Other: No intervention
- ProgenaBiome, Ventura, California
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
- Recurrent Malignant Mesothelioma
- Refractory Malignant Mesothelioma
- Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Drug: Cyclophosphamide
- Drug: Etoposide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility and Clinical Results of Implementation of ERAS® Guidelines for Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: an International Prospective Cohort Study
- Peritoneal Diseases
- Other: Pre-ERAS® phase (current clinical practice)
- University of Texas Southwestern Medical Center, Dallas, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
- Lung Cancer
- Mesothelioma
- Diagnostic Test: Biomarker Testing (L)
- Drug: Systemic Treatment (T)
- Teton Cancer Institute, Idaho Falls, Idaho
- Oncology and Hematology of South Texas, Laredo, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene
- Mesothelioma
- Drug: VT3989
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: SGN-BB228
- University of California at San Francisco, San Francisco, California
- Sarah Cannon Research Institute at HealthONE - Denver, Denver, Colorado
- NYU Langone Hospital, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
- Lung Cancer
- Mesothelioma
- Radiation: MR-guided Linac
- Brigham & Women's Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Biological: pembrolizumab
- Call for Information (Investigational Site 0202), Los Angeles, California
- Call for Information (Investigational Site 0017), Los Angeles, California
- Call for Information (Investigational Site 0010), Boston, Massachusetts
- Call for Information (Investigational Site 0008), New Brunswick, New Jersey
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated With an Adoptive Cellular Therapy
- Mesothelioma
- Lung Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
SBRT With Immunotherapy for Mesothelioma
- Pleural Mesothelial Neoplasm
- Other: Immunotherapy
- Other: Quality-of-Life Assessment
- Radiation: Stereotactic Body Radiation Therapy
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: NGM707
- University of Southern California, Los Angeles, California
- Hoag Memorial Hospital Presbyterian, Newport Beach, California
- UCLA Medical Center, Santa Monica, California
- Georgetown University Medical Center, Washington, District of Columbia
- Florida Cancer Specialists - Sarasota - SCRI, Sarasota, Florida
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
- Dana-Farber Cancer Institute, Boston, Massachusetts
- START Midwest, LLC, Grand Rapids, Michigan
- Nebraska Cancer Specialists, Omaha, Nebraska
- Prisma Health - Upstate, Greenville, South Carolina
- University of Texas Southwestern Medical Center, Dallas, Texas
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Lung Small Cell Carcinoma
- Advanced Pleural Malignant Mesothelioma
- Stage III Lung Cancer AJCC v8
- Stage III Pleural Malignant Mesothelioma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Pleural Malignant Mesothelioma AJCC v8
- Drug: Cisplatin
- Drug: Elimusertib
- University of California Davis Comprehensive Cancer Center, Sacramento, California
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
- National Institutes of Health Clinical Center, Bethesda, Maryland
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- Peritoneal Mesothelioma
- Pleural Mesothelioma
- Small Cell Lung Cancer
- Drug: XmAb20717
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Drug: CTX-471
- Ocala Oncology Center, Ocala, Florida
- Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
- Hackensack University Medical Center, Hackensack, New Jersey
- Mt Sinai, New York, New York
- Duke University School of Medicine, Durham, North Carolina
- Institute for Translational Oncology Research (ITOR), Greenville, South Carolina
- Mary Crowley Cancer Research, Dallas, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- Malignant Mesothelioma
- Non-small Cell Lung Cancers
- Drug: PRT3645
- Florida Cancer Specialists, Sarasota, Florida
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
- Tennessee Oncology, PLLC, Nashville, Tennessee
- South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas
- NEXT Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility of the LUM Imaging System for Detection of Peritoneal Surface Malignancies
- Peritoneal Metastases
- Combination Product: LUM Imaging System
- Massachusetts General Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal Mesothelioma
- Mesothelioma
- Peritoneal Mesothelioma
- Drug: Nivolumab
- Drug: Ipilimumab
- The University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
- Advanced Lung Cancer
- Stage IV Non-Small Cell Lung Cancer
- Unresectable Non-Small Cell Lung Carcinoma
- Unresectable Stage III Non-Small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Stage IV Mesothelioma
- Immunotherapy
- Immune Checkpoint Inhibitors
- Other: Educational Video and QPL List
- Massachusetts General Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Nivolumab
- Drug: Pemetrexed
- Drug: Cisplatin or Carboplatin
- Memoiral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
- Mesothelioma (MPM)
- Drug: IK-930
- Massachusetts General Hospital, Boston, Massachusetts
- Start Midwest, Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center, New York, New York
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- Next Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study
- Malignant Mesothelioma
- Non-Small Cell Lung Carcinoma
- Pleural Disorder
- Device: Light Dosimetry for Intranoperative Therapy
- Procedure: Photodynamic Therapy
- Drug: Porfimer Sodium
- Roswell Park Cancer Institute, Buffalo, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- Mesothelioma
- Biological: LMB-100
- Drug: ipilimumab
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
- Mesothelioma
- Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Durvalumab
- University of California San Diego, La Jolla, California
- University of Miami, Miami, Florida
- Moffitt Cancer Center, Tampa, Florida
- Emory University, Atlanta, Georgia
- University of Chicago, Chicago, Illinois
- NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- Massaschusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan, Ann Arbor, Michigan
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota
- Morristown Medical/Atlantic Health, Morristown, New Jersey
- Jersey Shore University Medical Center, Neptune, New Jersey
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
- Memorial Sloan Kettering, New York, New York
- University of Cincinnati, Cincinnati, Ohio
- Cleveland Clinic Foundation, Cleveland, Ohio
- Penn State Cancer Institute, Hershey, Pennsylvania
- Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Allegheny Cancer Center, Pittsburgh, Pennsylvania
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- University of Texas Southwestern Medical Center, Dallas, Texas
- Baylor College of Medicine, Houston, Texas
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Biological: Safety
- Icahn School of Medicine Mount Sinai, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Mesotheliomas Pleural
- Drug: Pembrolizumab
- Procedure: Indocyanine Green (ICG) Image-Guided Surgery
- Drug: Cisplatin
- Drug: Pemetrexed
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
- Non Small Cell Lung Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- Banner Health, Gilbert, Arizona
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- Stanford University, Palo Alto, California
- UCLA Medical Center, Santa Monica, California
- Mayo Clinic Jacksonville, Jacksonville, Florida
- Moffitt Cancer Center, Tampa, Florida
- Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic Rochester, Rochester, Minnesota
- Washington University, Saint Louis, Missouri
- NYU Langone Medical Center, New York, New York
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutchinson Cancer Center, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Malignant Pleural Mesothelioma
- Drug: INBRX-109
- HonorHealth Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Valkyrie Clinical Trials, Los Angeles, California
- Sarcoma Oncology Center, Santa Monica, California
- University of Colorado Hospital, Aurora, Colorado
- Emory University - Winship Cancer Institute, Atlanta, Georgia
- The University of Chicago, Chicago, Illinois
- University of Michigan, Ann Arbor, Michigan
- START Midwest Michigan, PC, Grand Rapids, Michigan
- Haley Phelan, New York, New York
- Cleveland Clinic, Cleveland, Ohio
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
- UT MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
- NEXT Oncology - Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: MRTX1719
- Mayo Clinic, Phoenix, Arizona
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado
- Mayo Clinic, Jacksonville, Florida
- Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic, Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center, New York, New York
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- START Center for Cancer Care, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of Pembrolizumab Plus Cryoablation in Patients With Unresectable Mesotheliomas
- Lung Cancer
- Unresectable Mesothelioma
- Drug: Pembrolizumab
- Procedure: Image-guided cryoablation
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- Pleural Mesothelioma
- Drug: Pembrolizumab
- Drug: Cisplatin and Pemetrexed
- University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
- Primary Peritoneal Carcinoma
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: PRO1184
- HonorHealth, Scottsdale, Arizona
- University of California Los Angeles Medical Center, Los Angeles, California
- University of California, San Diego; Moores Cancer Center, San Diego, California
- Providence Medical Foundation, Santa Rosa, California
- University of Kansas Medical Center (KUMC), Westwood, Kansas
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Karmanos Cancer Institute, Detroit, Michigan
- University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
- Mary Crowley Cancer Research, Dallas, Texas
- START Mountain Region, West Valley City, Utah
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
- Malignant Mesothelioma
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Pleural Mesothelioma
- Drug: MDNA11 Monotherapy
- Drug: MDNA11 in combination with checkpoint inhibitor
- Providence Saint John's Health Center, Santa Monica, California
- Boca Raton Regional Hospital, Boca Raton, Florida
- Orlando Health Cancer Institute, Orlando, Florida
- Emory - Winship Cancer Institute, Atlanta, Georgia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
- Procedure: Cytoreductive surgery
- Drug: LMB-100
- Diagnostic Test: Immunohistochemical Assay for Mesothelin
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance
- Pleural Effusion, Malignant
- Ascites, Malignant
- Mesothelioma
- xCures, Oakland, California
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
- Mesothelioma
- Non-small Cell Lung Cancer (NSCLC), Non-squamous
- Drug: TAK-500
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado
- Sarah Cannon Research Institute, Denver, Colorado
- Dana Farber Cancer Institute, Boston, Massachusetts
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- START South Texas Accelerated Research Therapeutics, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- BAP1 Gene Mutation
- Mesothelioma
- The Ohio State University Wexner Medical Center, Columbus, Ohio
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
- Mesothelioma
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- Drug: Fludarabine + Cyclophosphamide combination
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Pembrolizumab
- Radiation: IMPRINT
- Memoral Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: HFB200301
- Mayo Clinic, Scottsdale, Arizona
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- Mayo Clinic, Jacksonville, Florida
- Mayo Clinic, Rochester, Minnesota
- Washington University School of Medicine, Saint Louis, Missouri
- The University of Texas, MD Anderson Cancer Center, Houston, Texas
- NEXT Virginia Cancer Specialists, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
- Drug: ASTX295
- City of Hope Comprehensive Cancer Center, Duarte, California
- Cedars-Sinai Medical Center, Los Angeles, California
- Hoag Hospital, Newport Beach, California
- Holden Comprehensive Cancer Center, Iowa City, Iowa
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
- Columbia University Irving Medical Center - Herbert Irving Pavilion, New York, New York
- University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
- Virgnia Cancer Specialists, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
- Mesothelioma
- Drug: IAG933
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts
- Cleveland Clinic Foundation, Cleveland, Ohio
- MD Anderson Cancer Center/University of Texas, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: AG-01 Compound
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
- Recurrent Malignant Mesothelioma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Malignant Mesothelioma
- Resectable Malignant Mesothelioma
- Resectable Sarcoma
- Drug: Cisplatin
- Procedure: Cytoreductive Surgery
- Drug: Doxorubicin
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Sodium Thiosulfate
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma
- Epitheliod Malignant Pleural Mesothelioma
- Radiation: Photodynamic Therapy
- Procedure: Radical Pleurectomy
- Radiation: Chemotherapy
- Drug: Photofrin 2.0 mg/kg
- Rosewell Park, Buffalo, New York
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Drug: TNG908
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Washington University, Saint Louis, Missouri
- Sarah Cannon Tennessee Oncology, Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
- NEXT Oncology, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
- Drug: ENV-101 (taladegib)
- Research Site, Los Angeles, California
- Research Site, San Diego, California
- Research Site, Santa Monica, California
- Research Site, Tampa, Florida
- Research Site, Zion, Illinois
- Research Site, Covington, Louisiana
- Research Site, Las Vegas, Nevada
- Research Site, New York, New York
- Research Site, Durham, North Carolina
- Research Site, Cincinnati, Ohio
- Research Site, Cleveland, Ohio
- Research Site, Columbus, Ohio
- Research Site, Pittsburgh, Pennsylvania
- Research Site, Nashville, Tennessee
- Research Site, Houston, Texas
- Research Site, Fredericksburg, Virginia
- Research Site, Lynchburg, Virginia
- Research Site, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies
- Metastatic Cancer
- Drug: Sym024
- START Midwest, Grand Rapids, Michigan
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies
- Malignant Pleural Mesotheliomas NOS
- Lung Cancer NOS
- Thoracic Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
- Pleural Biphasic Mesothelioma
- Pleural Epithelioid Mesothelioma
- Stage I Pleural Malignant Mesothelioma AJCC v8
- Stage IA Pleural Malignant Mesothelioma AJCC v8
- Stage IB Pleural Malignant Mesothelioma AJCC v8
- Stage II Pleural Malignant Mesothelioma AJCC v8
- Stage IIIA Pleural Malignant Mesothelioma AJCC v8
- Drug: Carboplatin
- Drug: Cisplatin
- Procedure: Decortication
- Drug: Pemetrexed
- Drug: Pemetrexed Disodium
- Procedure: Pleurectomy
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
- Moffitt Cancer Center-International Plaza, Tampa, Florida
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida
- Moffitt Cancer Center, Tampa, Florida
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Brigham and Women's Hospital, Boston, Massachusetts
- Mayo Clinic in Rochester, Rochester, Minnesota
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Mount Sinai Hospital, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
- Cleveland Clinic Foundation, Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- MD Anderson in The Woodlands, Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
- M D Anderson Cancer Center, Houston, Texas
- MD Anderson West Houston, Houston, Texas
- MD Anderson League City, League City, Texas
- MD Anderson in Sugar Land, Sugar Land, Texas
- Swedish Medical Center-First Hill, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: NGM438
- Yale Cancer Center, New Haven, Connecticut
- Henry Ford Health System, Detroit, Michigan
- START Midwest, Grand Rapids, Michigan
- Mount Sinai Hospital, New York, New York
- MD Anderson, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
- Drug: KZR-261
- Cedars Sinai Medical Center, Los Angeles, California
- Moffitt Cancer Center, Tampa, Florida
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville, Nashville, Tennessee
- START (South Texas Accelerated Research Therapeutics), San Antonio, Texas
- Virginia Cancer Specialists (VCS), Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
- Small-cell Lung Cancer
- Mesothelioma
- Drug: INCB099318
- Hackensack University Medical Center, Hackensack, New Jersey
- Prisma Health Cancer Institute Faris, Greenville, South Carolina
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
- Mesothelioma
- Squamous Cell Carcinoma of Lung
- Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
- City of Hope National Medical Center, Duarte, California
- Atlantic Health System, Morristown Medical Center, Morristown, New Jersey
- Weill-Cornell Medicine, Cornell University, New York, New York
- Gabrail Cancer Center Research, Canton, Ohio
- Erlanger Health System (Hospital); University of Tennessee College of Medicine, Chattanooga, Chattanooga, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Medical College of Wisconsin, Milwaukee, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Mesothelioma
- Other: MPT Test
- Other: CLDN15/VIM Test
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Peritoneal Malignant Mesothelioma
- Biological: Atezolizumab
- Biological: Bevacizumab
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Procedure: Computed Tomography
- Procedure: Cytoreductive Surgery
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Pemetrexed
- Procedure: Positron Emission Tomography
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Carle on Vermilion, Danville, Illinois
- Carle Physician Group-Effingham, Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois
- Carle Cancer Center, Urbana, Illinois
- The Carle Foundation Hospital, Urbana, Illinois
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts
- Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
- Fairview Southdale Hospital, Edina, Minnesota
- Unity Hospital, Fridley, Minnesota
- Abbott-Northwestern Hospital, Minneapolis, Minnesota
- Mayo Clinic in Rochester, Rochester, Minnesota
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota
- Regions Hospital, Saint Paul, Minnesota
- United Hospital, Saint Paul, Minnesota
- Sanford Bismarck Medical Center, Bismarck, North Dakota
- Sanford Broadway Medical Center, Fargo, North Dakota
- Sanford Roger Maris Cancer Center, Fargo, North Dakota
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
- M D Anderson Cancer Center, Houston, Texas
- Marshfield Medical Center-Marshfield, Marshfield, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
- Mesothelioma
- Peritoneal Mesothelioma
- Diagnostic Test: HR-MRI
- Diagnostic Test: Standard CT Imaging
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Mesothelioma
- Drug: APG-5918
- Highlands Oncology, Springdale, Arkansas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Integrated Cancer Repository for Cancer Research
- Lung Cancer
- Peritoneal Surface Malignancies
- Mesothelioma
- Penrose Cancer Center, Colorado Springs, Colorado
- Porter Adventist Hospital, Denver, Colorado
- Mercy Regional Medical Center, Durango, Colorado
- St. Anthony Hospital, Lakewood, Colorado
- Littleton Cancer Center, Littleton, Colorado
- Longmont Cancer Center, Longmont, Colorado
- Avista Cancer Center, Louisville, Colorado
- Parker Adventist Hospital, Parker, Colorado
- St. Mary Corwin Medical Center, Pueblo, Colorado
- St. Anthony North Cancer Center, Westminster, Colorado
- Florida Hospital Memorial Medical Center, Daytona Beach, Florida
- Florida Hospital DeLand, DeLand, Florida
- Florida Hospital FISH, Orange City, Florida
- Florida Hospital Flagler, Palm Coast, Florida
- Tallahassee Memorial Hospital, Tallahassee, Florida
- Rush-Copley Cancer Care Center, Aurora, Illinois
- Trinity Medical Center, Moline, Illinois
- Rush-Copley Healthcare Center, Yorkville, Illinois
- Parkview Research Center, Fort Wayne, Indiana
- Community Health Network, Indianapolis, Indiana
- Community Cancer Center South, Indianapolis, Indiana
- Community Cancer Center North, Indianapolis, Indiana
- Community Howard Regional Hospital, Kokomo, Indiana
- Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa
- Genesis Medical Center, Davenport, Iowa
- Abben Cancer Center, Spencer, Iowa
- Covenant Medical Center, Inc, Waterloo, Iowa
- Saint Luke's Cancer Instititue - South, Overland Park, Kansas
- Tulane University, New Orleans, Louisiana
- Breast Care Specialists of Maine, Portland, Maine
- Northwest Hospital, Randallstown, Maryland
- William E Kahlert Regional Cancer Center, Westminster, Maryland
- Holyoke Medical Center, Holyoke, Massachusetts
- University of Michigan Health System, Ann Arbor, Michigan
- Riverwood Healthcare Center, Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center, Brainerd, Minnesota
- Essentia Health - Duluth Clinic, Duluth, Minnesota
- St. Luke's Hospital of Duluth, Duluth, Minnesota
- Lake Region Healthcare, Fergus Falls, Minnesota
- Avera Cancer Institute- Marshall, Marshall, Minnesota
- Mercy Hospital - Joplin, Joplin, Missouri
- Saint Luke's Cancer Institute - East, Kansas City, Missouri
- Saint Luke's Cancer Institute, Kansas City, Missouri
- Saint Luke's Cancer Institute - Kansas City North, Kansas City, Missouri
- Saint Luke's Cancer Institute - Liberty, Liberty, Missouri
- Heartland Regional Medical Center dba Mosaic Life Care, Saint Joseph, Missouri
- Bozeman Health Deaconess Hospital, Bozeman, Montana
- Logan Health, Kalispell, Montana
- Providence St. Patrick Hospital Montana Cancer Center, Missoula, Montana
- Mary Lanning Healthcare/Morrison Cancer Center, Hastings, Nebraska
- Faith Regional Health Services, Carson Cancer Center, Norfolk, Nebraska
- Great Plains Regional Medical Center, North Platte, Nebraska
- Avera St. Anthony's Hospital, O'Neill, Nebraska
- Methodist Estabrook Cancer Center, Omaha, Nebraska
- Nebraska Methodist Health System, Omaha, Nebraska
- University of Nebraska Medical Center, Omaha, Nebraska
- Regional West Health Services, Scottsbluff, Nebraska
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls, New York
- Faxton St. Luke's Healthcare/Mohawk Valley, Utica, New York
- Cape Fear Valley Health System, Fayetteville, North Carolina
- Essentia Health, Fargo, North Dakota
- Trinity Hospital Cancer Care Center, Minot, North Dakota
- Aultman Alliance Community Hospital, Alliance, Ohio
- Aultman Hospital, Canton, Ohio
- University of Pittsburgh, Pittsburgh, Pennsylvania
- Avera Medical Group Oncology and Hematology Aberdeen, Aberdeen, South Dakota
- Avera Cancer Institute, Mitchell, South Dakota
- Avera Cancer Institute, Sioux Falls, South Dakota
- Sanford Health, Sioux Falls, South Dakota
- Avera Cancer Center Yankton, Yankton, South Dakota
- Avera Sacred Heart Hospital, Yankton, South Dakota
- Yankton Medical Clinic, Yankton, South Dakota
- Rutland Regional Medical Center, Rutland, Vermont
- Mary Washington Hospital, Fredericksburg, Virginia
- Ascension St. Elizabeth Hospital, Appleton, Wisconsin
- Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital, Brookfield, Wisconsin
- Wheaton Franciscan Healthcare - Reiman Cancer Care, Franklin, Wisconsin
- Bellin Memorial Hospital, Green Bay, Wisconsin
- Columbia St. Mary's, Mequon, Wisconsin
- Columbia St. Mary's, Milwaukee, Wisconsin
- Ascension Mercy Hospital, Oshkosh, Wisconsin
- Wheaton Franciscan Healthcare - All Saints, Racine, Wisconsin
- Wheaton Franciscan Healthcare - Wauwatosa Cancer Care, Wauwatosa, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
- Mesothelioma, Malignant
- Drug: CPI-0209
- Emory University Hospital, Atlanta, Georgia
- University of Chicago Medical Center, Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan, Ann Arbor, Michigan
- START Midwest, Grand Rapids, Michigan
- Hackensack University Medical Center, Hackensack, New Jersey
- Montefiore Einstein Center for Cancer Care, Bronx, New York
- NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center, New York, New York
- University of Cincinnati Medical Center, Cincinnati, Ohio
- START San Antonio, San Antonio, Texas
- University of Virginia Cancer Center, Charlottesville, Virginia
- Swedish Cancer Institute, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: NGM831
- Banner MD Anderson Medical Center, Gilbert, Arizona
- The Angeles Clinic, Los Angeles, California
- Florida Cancer Specialists, Sarasota, Florida
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
- START Midwest, Grand Rapids, Michigan
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
- Next Oncology, Austin, Texas
- The University of Texas - MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
- Stage III Lung Cancer
- Stage IV Lung Cancer
- Malignant Pleural Effusion
- Malignant Ascites
- Mesothelioma
- Columbus Regional Research Institute, John B. Amos Cancer Center, Columbus, Georgia
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
- Lung Adenocarcinoma
- Peritoneal Carcinoma
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Biological: huCART-meso cells
- University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- Malignant Pleural Mesothelioma (MPM)
- Drug: NX-1607
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
- Mesothelioma
- Drug: Olaparib
- University of Chicago Medical Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
- Small-cell Lung Cancer
- Mesothelioma
- Drug: INCB099280
- Dana Farber Cancer Institute, Boston, Massachusetts
- Henry Ford Hospital, Detroit, Michigan
- Upmc Cancercenter, Pittsburgh, Pennsylvania
- Md Anderson Cancer Center, Houston, Texas
- University of Washington, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Mesothelioma
- Drug: SO-C101
- Yale Cancer Center, New Haven, Connecticut
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
- Soft Tissue Sarcoma (Excluding GIST)
- Mesothelioma
- Drug: Lurbinectedin
- Drug: Irinotecan
- Massachusetts General Hospital -, Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
- The University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (855) 947–1097 to get started
Trial Name
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
- Drug: IDE397
- Honor Health Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Indiana University Health Hospital, Indianapolis, Indiana
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
- Dana Farber Cancer Institute, Boston, Massachusetts
- Columbia University Medical Center - Herbert Irving Pavilion, New York, New York
- Weill Cornell Medical College, New York, New York
- Stephenson Cancer Center, Oklahoma City, Oklahoma
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee
- MD Anderson, Houston, Texas
- Next Oncology, San Antonio, Texas
How to Participate in a Mesothelioma Clinical Trial
Mesothelioma patients looking to get involved in a clinical trial should work closely with their doctors to determine which trials may be most helpful to them and how to sign up.
To enroll in a mesothelioma clinical trial, patients may take the following steps:
- Find clinical trials: Patients can work with their doctors to find clinical trials for mesothelioma for which they qualify. Individuals may wish to reach out to another mesothelioma specialist, mesothelioma organizations, or websites to see if they are eligible for additional clinical trials.
- Review trial information: Patients should review clinical trial information with their doctors and families to determine what is best for them and their loved ones. Paying special attention to a clinical trial’s consent form should help the individual know what to expect in terms of treatment, costs, and more.
- Ask questions: Patients should ask their doctors any questions they have about the trials they are considering before making a final decision.
- Choose a trial: Once they are comfortable with their choice, mesothelioma patients can tell their medical team that they wish to enroll in a mesothelioma clinical trial. The team will guide them through the process of applying.
Anyone interested in joining a clinical trial should speak with their doctor about the active clinical trials they may be eligible to join.
Common screening factors for mesothelioma clinical trials include:
- Past treatment history
- Patient health and medical conditions
- Stage of mesothelioma
- Type of mesothelioma
After determining which clinical trials for mesothelioma a patient is eligible for, it may still be difficult to know which clinical trial to enroll in. However, asking one’s doctor relevant questions is an important part of making a sound choice.
Questions to Ask Your Doctor About Clinical Trials
Mesothelioma doctors are a vital source not just for standard care, but for finding, selecting, and enrolling in mesothelioma clinical trials.
Questions to ask about clinical trials for mesothelioma:
- Do you know of any clinical trials I could join?
- What organization is behind this trial?
- What is the purpose of this trial?
- What tests and treatments does this study involve?
- What does the treatment do?
- Has this treatment been used on mesothelioma patients before?
- Will I know if I receive the new treatment or if I’m part of the control group?
- What are the benefits and the risks of participating in this trial?
- How might this study impact my daily life and current treatment plan?
- Where will I need to go to participate in this study?
- What will this study cost me? Are there any associated expenses I should be aware of like travel costs?
- What long-term follow-up care does this clinical trial include?
Patients should take advantage of their doctor’s expertise and ask any and all questions they have regarding mesothelioma clinical trials. This includes clarification on any terms they may not know.
Get Help Enrolling in a Clinical Trial
Each clinical trial has eligibility requirements that patients must meet before being accepted into a study.
Patients should consult with a mesothelioma specialist to discuss the risks and benefits of participating in mesothelioma clinical trials. Patients must also consider what trials they qualify for given their mesothelioma location, stage, and cell type.
To get help joining a mesothelioma clinical trial, contact the Mesothelioma Hope team today.
Mesothelioma Clinical Trials FAQs
Are there any clinical trials for mesothelioma?
Yes, there are many clinical trials for mesothelioma that are currently recruiting patients or will be soon.
A December 2022 search of clinicaltrials.gov — a database of clinical trials being performed worldwide — showed about 120 active mesothelioma clinical trials.
While some of the clinical trials were recruiting patients, others were not yet recruiting, enrolling patients by invitation, or active but not recruiting.
Not every mesothelioma clinical trial is right for every patient.
Your mesothelioma doctor and care team can provide you with information about clinical trials that might be suitable for you.
Are there any new treatments for mesothelioma?
Yes, there are several new treatments for mesothelioma that are being investigated in clinical trials.
For example, researchers are looking at immunotherapy and targeted therapy as possible treatments for mesothelioma.
Immunotherapy helps the body’s own immune system while targeted therapy attacks cancer cells but leaves healthy cells alone.
Scientists are also turning to nature as they develop anticancer medications that may be helpful in the fight against mesothelioma. For example, one drug derived from the periwinkle plant and another from frog eggs have shown promise.
